A Study on Pregenomic RNA and Factors Related to Hepatitis B Virus Infection Based on Real World

Overview

Journal Front Public Health

Specialty Public Health

Date 2022 Jul 5

PMID 35784246

Authors

Hao-Zhen Yan

Zhi-Hao Huang

Xu-Guang Guo

Ting-Ting Peng

Li-Li Yang

Chong-Wen Liu

Shi Ou-Yang

Affiliations

Soon will be listed here.

Abstract

Objective: This article aims to study the influencing factors of pgRNA and its change magnitude based on the real world.

Methods: A total of 421 patients who were tested for pgRNA were selected. According to the baseline data, the subjects were divided into negative and positive groups. The Chi-square test and logistic regression were used to analyze the influencing factors of pgRNA status. Based on the follow-up data, the rank-sum test and linear regression were used to analyze the influencing factors of pgRNA change magnitude.

Results: A total of 153 (36.3%) of the 421 subjects were pgRNA-negative and 268 (63.7%) were pgRNA-positive. Logistic regression analysis showed that positive HBV DNA (OR: 40.51), positive HBeAg (OR: 66.24), tenofovir treatment (OR: 23.47), and entecavir treatment (OR: 14.90) were the independent risk factors for positive pgRNA. Univariate linear regression showed that the pgRNA change magnitude of patients treated with entecavir was higher than that of patients treated with tenofovir. Multivariate linear regression showed that age was an independent factor influencing pgRNA change magnitude.

Conclusions: The pgRNA of patients who were young, female, HBV DNA-positive, high-HBsAg, HBeAg-positive is higher than the detection line. HBV DNA and HBeAg are the independent risk factors of positive pgRNA. Different antiviral regimens and disease stages have significantly different effects on pgRNA status. There was a significant correlation between pgRNA and FIB-4, suggesting that pgRNA is related to liver fibrosis. The decrease in pgRNA was greater in young patients than in non-young patients. The decrease in pgRNA was greater in patients treated with tenofovir than in patients treated with entecavir.

Citing Articles

The Levels of Serum HBV Pre-Genomic RNA and Its Associated Factors Among HBV-Infected Patients: A Retrospective Cohort Study in Hangzhou, Zhejiang, China.

Zuo Z, Wu J, Wang M, Wu R, Zhang X, Hu L Int J Gen Med. 2024; 17:4669-4680.

PMID: 39429953 PMC: 11490237. DOI: 10.2147/IJGM.S480283.

Time-course analysis of antibody and cytokine response after the third SARS-CoV-2 vaccine dose.

Kim H, Lee H, Hennighausen L, Furth P, Sung H, Huh J Vaccine X. 2024; 20:100565.

PMID: 39399820 PMC: 11470517. DOI: 10.1016/j.jvacx.2024.100565.

References

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

Pan J, Xu J, Luo H, Tan N, Kang Q, Chen H . Factors and virological significance of hepatitis B virus pregenomic RNA status after 5 years of antiviral therapy. Int J Infect Dis. 2021; 105:418-423. DOI: 10.1016/j.ijid.2021.02.116. View

Kramvis A, Kew M . The core promoter of hepatitis B virus. J Viral Hepat. 1999; 6(6):415-27. DOI: 10.1046/j.1365-2893.1999.00189.x. View

Butler E, Gersch J, McNamara A, Luk K, Holzmayer V, de Medina M . Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection. Hepatology. 2018; 68(6):2106-2117. DOI: 10.1002/hep.30082. View

Levrero M, Testoni B, Zoulim F . HBV cure: why, how, when?. Curr Opin Virol. 2016; 18:135-43. DOI: 10.1016/j.coviro.2016.06.003. View

Chang J, Guo F, Zhao X, Guo J . Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharm Sin B. 2015; 4(4):248-57. PMC: 4629125. DOI: 10.1016/j.apsb.2014.05.002. View

Na J, Kim J, Choe W, Kwon S, Yoo B . Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients. Korean J Gastroenterol. 2021; 77(6):285-293. DOI: 10.4166/kjg.2021.043. View

Kim Y, Cho H, Choi M, Lee J, Koh K, Yoo B . The change of the quantitative HBsAg level during the natural course of chronic hepatitis B. Liver Int. 2011; 31(6):817-23. DOI: 10.1111/j.1478-3231.2011.02516.x. View

Mu D, Yuan F, Chen Y, Jiang X, Yan L, Jiang L . Baseline value of intrahepatic HBV DNA over cccDNA predicts patient's response to interferon therapy. Sci Rep. 2017; 7(1):5937. PMC: 5517439. DOI: 10.1038/s41598-017-05242-y. View

10.

de Niet A, Jansen L, Stelma F, Willemse S, Kuiken S, Weijer S . Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. Lancet Gastroenterol Hepatol. 2017; 2(8):576-584. DOI: 10.1016/S2468-1253(17)30083-3. View

11.

Dong J, Ying J, Qiu X, Lu Y, Zhang M . Advanced Strategies for Eliminating the cccDNA of HBV. Dig Dis Sci. 2017; 63(1):7-15. DOI: 10.1007/s10620-017-4842-1. View

12.

Liu Y, Jiang M, Xue J, Yan H, Liang X . Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol. 2019; 19(1):53. PMC: 6469196. DOI: 10.1186/s12876-019-0966-4. View

13.

Lin N, Ye A, Lin J, Liu C, Huang J, Fu Y . Diagnostic Value of Detection of Pregenomic RNA in Sera of Hepatitis B Virus-Infected Patients with Different Clinical Outcomes. J Clin Microbiol. 2019; 58(2). PMC: 6989074. DOI: 10.1128/JCM.01275-19. View

14.

Yang C, Huang E, Li H, Su P, Shih C . Nuclear export of human hepatitis B virus core protein and pregenomic RNA depends on the cellular NXF1-p15 machinery. PLoS One. 2014; 9(10):e106683. PMC: 4215830. DOI: 10.1371/journal.pone.0106683. View

15.

Ma X, Liu S, Wang M, Wang Y, Du S, Xin Y . Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis. J Clin Transl Hepatol. 2021; 9(3):335-344. PMC: 8237148. DOI: 10.14218/JCTH.2020.00164. View

16.

Raftery N, Stevenson N . Advances in anti-viral immune defence: revealing the importance of the IFN JAK/STAT pathway. Cell Mol Life Sci. 2017; 74(14):2525-2535. PMC: 7079803. DOI: 10.1007/s00018-017-2520-2. View

17.

Gao L, Trinh H, Li J, Nguyen M . Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther. 2014; 39(6):629-37. PMC: 3999385. DOI: 10.1111/apt.12629. View

18.

Lamontagne R, Bagga S, Bouchard M . Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2017; 2:163-186. PMC: 5198785. DOI: 10.20517/2394-5079.2016.05. View

19.

Shen F, Li Y, Wang Y, Sozzi V, Revill P, Liu J . Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype. Hepatology. 2017; 67(4):1237-1252. DOI: 10.1002/hep.29609. View

20.

Giersch K, Allweiss L, Volz T, Dandri M, Lutgehetmann M . Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2016; 66(2):460-462. DOI: 10.1016/j.jhep.2016.09.028. View